CXCR1 and head and neck squamous cell carcinoma: We have identified an additional phase I/II trial treating patients with metastatic TNBC or p16-negative head and neck squamous cell carcinoma (HNSCC) with bintrafusp alfa, the cancer vaccine MVA-BN-CV301/FPV-CV301, and SX-682, a small molecule inhibitor of CXCR1/2 (NCT04574583).